30Sep, 14Press Release, Moscow, October, 2014Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry...
29Oct, 18MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta at the AASLD Meeting in San FranciscoBAD HOMBURG, Germany, October 29, 2018 / PRNewswire / -- MYR Pharma today announced that the results of 48 weeks of...
13Apr, 19ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression bILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with...
23Oct, 18MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D InfectionsMYR Pharma today announced that US Food and Drug Administration (FDA) has granted the Breakthrough Therapy designation...
